Novartis Ag

Ciba-geigy Corporation

Novartis Corporation

Other

Novartis Pharma Gmbh

David Thomas Parker

Jiping Fu

Aregahegn Yifru

Prakash Raman

Mohindra Seepersaud

Pascal Rigollier

Rui Zheng

Kayo Yasoshima

Francois Lenoir

Yunshan Peng

Michael A Patane

Stefan Peukert

Fupeng Ma

Gregory Raymond Bebernitz

Trixi Brandl

Mahavir Prashad

Peichao Lu

Qi-Ying Hu

Frederic Zecri

Ruben Alberto Tommasi

Lawrence J MacPherson

Lv Liao

Oliver Simic

Ken Yamada

Branko Radetich

Hatice Belgin Gulgeze Efthymiou

Guillaume Barbe

Sicong Geng

Ruowei Mo

Nichola Smith

Yugang Liu

Sompong Wattanasin

Subramanian Karur

Lech Andrzej Ciszewski

Shawn D Britt

Leslie Wighton McQuire

Philipp Grosche

Hidetomo Imase

Benjamin B Mugrage

Lauren Gilchrist Monovich

Roger A Fujimoto

Hongjuan Zhao

Andrei Alexandrovich Golosov

Frédéric Zecri

Arco Yingcheu Jeng

Leslie Ann Robinson

Grazia Piizzi

Philippe G Nantermet

Joshua David Parker

Jacob Thomas Parker

John H VanDuzer

Markus Rolf Dobler

Roger Aki Fujimoto

Jerry W Skiles

Philippe Nantermet

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R, R-R, Xand Xare as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Naphthyridinone derivatives and their use in the treatment of arrhythmia

A flying toy system capable of independently hovering at a programmable height and respond to the manipulations and/or actions of one or more users through their fingers or similar digit extensions, all while continuing an autonomous flight regime.

Finger flying hover toy

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;  Wherein R, R-R, Xand Xare as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention provides a synthetic polypeptide of Formula I': 

Synthetic apelin mimetics for the treatment of heart failure

The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.

Organic compounds and their uses

The present application describes organic compounds of a general formula: 

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

The present application describes organic compounds of the Formula I that are useful for the treatment, prevention and/or amelioration of human diseases. 

Certain phenylacetic acids and derivatives

The present invention relates to the alpha-(N-substituted pyrrolidinyl and piperidinyl) alpha-(arysulfonamido)-aceto-hydroxamic acids of formula I ##STR1## wherein R represents acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; or R represents (lower alkyl, aryl-lower alkyl or aryl)-sulfonyl, di-(aryl-lower alkyl or alkyl)-aminosulfonyl, or aryl-lower alkyl; Ar represents carbocyclic aryl, heterocyclic aryl or biaryl; R.sub.1 and R.sub.2 represent independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R.sub.1 and R.sub.2 together on adjacent carbon atoms represent lower alkylenedioxy; m represents zero or one; n represents an integer from 1 to 5; pharmaceutically acceptable prodrug derivatives thereof; and pharmaceutically acceptable salts thereof; further to a process for the preparation of these compounds, to pharmaceutical compositions comprising these compounds, to the use of these compounds for the therapeutic treatment of the human or animal body or for the manufacture of a pharmaceutical composition.

Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic

Particularly the invention relates to the compounds of formula I ##STR1## wherein Ar represents carbocyclic aryl, heterocyclic aryl or biaryl;

Certain alpha-substituted arylsulfonamido acetohydroxamic acids

Disclosed are the compounds of formula I ##STR1## wherein R and R.sub.1 together with the chain to which they are attached or R.sub.1 and R.sub.2 together with the carbon atom to which they are attached form a ring; pharmaceutically acceptable prodrug derivatives and pharmaceutically salts thereof; methods of preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting matrix-degrading metalloproteinase and of treating matrix-degrading metalloproteinase dependent conditions in mammals using such compounds.

Arylsulfonamido-substituted hydrodxamic acids

Growing community of inventors

Lexington, MA, United States of America

David Thomas Parker